Background: There is a large amount of evidence that anti-angiogenic drugs are effective safe. However, few studies have evaluated the specific effects of anti-angiogenic drugs on myocardial enzyme injury biomarkers: aspartate aminotransferase (AST), lactic dehydrogenase (LDH), creatine kinase (CK) and creatine kinase isoenzyme (CK-MB). The purpose of our study was to determine whether anti-angiogenic drugs serum AST, LDH, CK, and CK-MB activities of cancer patients treated with anti-angiogenic drugs.

Methods: This study retrospectively analyzed 81 cancer patients. Patients who had used anti-angiogenic drugs were selected. Serum AST, LDH, CK, and CK-MB activities were measured before and after treatment with anti-angiogenic drugs for 3 weeks.

Results: A total of 16 cancer types were analyzed. The distribution of the cancer types in the patients was mainly concentrated in lung, gastric, and colorectal cancers. The anti-angiogenic treatment markedly increased AST, LDH, CK, and CK-MB activities by 32.51, 7.29, 31.25, and 55.56%, respectively in serum.

Conclusions: Our findings suggest that patients, who had used anti-angiogenic drugs were likely to have elevated AST, LDH, and CK, indicators of myocardial muscle injury. Use of anti-angiogenic drugs should not be assumed to be completely safe and without any cardiovascular risks.

背景：大量证据表明抗血管生成药物是有效、安全的。然而，很少有研究评估抗血管生成药物对心肌酶损伤生物标志物：天冬氨酸转氨酶（AST）、乳酸脱氢酶（LDH）、肌酸激酶（CK）和肌酸激酶同工酶（CK-MB）的具体影响。我们研究的目的是确定抗血管生成药物是否会影响接受抗血管生成药物治疗的癌症患者的血清 AST、LDH、CK 和 CK-MB 活性。

方法：本研究回顾性分析了 81 名癌症患者。选择使用过抗血管生成药物的患者。测定抗血管生成药物治疗3周前后血清AST、LDH、CK、CK-MB活性。

结果：总共分析了 16 种癌症类型。患者癌症类型分布主要集中在肺癌、胃癌和结直肠癌。抗血管生成治疗使血清中 AST、LDH、CK 和 CK-MB 活性分别显着增加 32.51%、7.29%、31.25% 和 55.56%。

结论：我们的研究结果表明，使用抗血管生成药物的患者可能出现 AST、LDH 和 CK 升高，这些指标是心肌损伤的指标。不应认为抗血管生成药物的使用是完全安全的并且没有任何心血管风险。